DUBLIN, June 4, 2026, 16:06 (Irish Standard Time)
ICON plc (NASDAQ:ICLR) moved up 5.1% to $151.21 Thursday morning in New York, adding to gains after closing an accounting investigation. Investors shifted focus to company bookings, new guidance, and several analyst price target bumps. ICON traded as high as $152.07 after starting the session at $144.28.
ICON had spent months dealing with pressure on revenue recognition, backlog quality, and internal controls. That’s important now. TipRanks noted 20 hours ago that the latest move showed some relief as the audit committee investigation wrapped up. Focus now shifts back to fourth-quarter bookings and the 2026 outlook.
ICON released results last week after its audit committee flagged improper changes to clinical trial services revenue, moving numbers from Q3 2023 into Q4 2024. The company restated, saying revenue was overstated by 0.8% in 2023 and 1.1% in 2024. ICON said this didn’t impact customers, operations, or cash flow.
Buyers got some numbers to pick over. Fourth-quarter revenue came in at $2.11 billion with adjusted EBITDA of $327.1 million. Net business wins were $2.87 billion. Book-to-bill landed at 1.36, showing new work still ahead of revenue.
ICON CEO Barry Balfe said the company is “actively building a stronger control environment” following the probe. He also noted “strong net bookings” for the quarter. ICON set 2026 revenue guidance between $7.85 billion and $8.15 billion, with adjusted diluted EPS at $10.00 to $11.00. ICON plc
TD Cowen bumped its price target for the stock to $164 from $120 and stuck with its Buy rating. Analysts there said the end of the investigation reset the shares, and they pointed to fourth-quarter bookings for momentum. Not all analysts acted the same way.
BMO Capital’s Sean Dodge bumped his price target up to $160 from $130 and held his Outperform call, citing the clean accounting review and stronger demand. Citi’s Patrick Donnelly also raised his target, to $140 from $120, but kept a Neutral rating, calling the move more cautious after shares rallied.
Board changes followed the trade, with ICON saying Kevin Egan and Jeff Elliott are joining the board on June 1. Steve Cutler stepped down from the board on May 21. Chairman Ciaran Murray said the board is committed to the “highest standards of corporate governance.” ICON plc
CRO stocks moved up. IQVIA was up 2.6%, Medpace added 1.9%, and Charles River Laboratories rose 3.3%. The SPDR S&P 500 ETF traded a bit lower. Contract research organizations—CROs—are hired by drug companies to handle parts of clinical trials like patient recruitment and regulatory paperwork.
But the rebound doesn’t mean everything is fixed. ICON flagged material weaknesses, so there are significant control issues that could lead to misstated financials. Its 2026 revenue and adjusted EPS guidance are also lower than 2025 numbers. If ICON needs more time to fix its controls, or if pricing pressure and pass-through revenue keep margins under pressure, shares could lose some gains from the recent rally.
Next up is the test for the first quarter. Management said it expects awards and cancellations for the first quarter to be roughly in line. The team described the commercial setup for the second quarter as encouraging. ICON plans to report Q1 results in June and Q2 numbers in July.
